Cancer Prevention Research AACR Legacy Sign up for eTOC's!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Prevention Research 2, 566, June 1, 2009. Published Online First May 26, 2009;
doi: 10.1158/1940-6207.CAPR-08-0202
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1940-6207.CAPR-08-0202v1
2/6/566    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Khwaja, F. S.
Right arrow Articles by Djakiew, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khwaja, F. S.
Right arrow Articles by Djakiew, D.
Related Collections
Right arrow Preclinical Intervention
Right arrow Preclinical Intervention: In Vitro: Drugs, Mechanisms

Research Articles

3,3'-Diindolylmethane Induction of p75NTR-Dependent Cell Death via the p38 Mitogen-Activated Protein Kinase Pathway in Prostate Cancer Cells

Fatima S. Khwaja1, Shehla Wynne1, Isadora Posey2 and Daniel Djakiew1

Authors' Affiliations: 1 The Department of Biochemistry and Molecular and Cellular Biology and the Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center and 2 The Department of Chemistry and Physics, University of the District of Columbia, Washington, D.C.

Requests for reprints: Daniel Djakiew, Department of Biochemistry and Molecular and Cellular Biology, Georgetown University Medical Center, 3900 Reservoir Road Northwest, Washington, D.C. 20057-1436. Phone: 202-687-1203; Fax: 202-687-1823; E-mail: djakiewd{at}georgetown.edu.


The p75NTR functions as a tumor suppressor in prostate epithelial cells, where its expression declines with progression to malignant cancer. Previously, we showed that treatment with the nonsteroidal anti-inflammatory drug, indomethacin, induced p75NTR expression in the T24 cancer cell line leading to p75NTR-mediated decreased survival. Utilizing the indole moiety of indomethacin as a pharmacophore, we identified in rank-order with least efficacy, ketorolac, etodolac, indomethacin, 5-methylindole-3-acetic acid, indole-3-carbinol, and 3,3'-diindolylmethane (DIM) exhibiting greatest activity for induction of p75NTR levels and inhibition of cell survival. Prostate (PC-3, DU-145) and bladder (T24) cancer cells were more sensitive to DIM induction of p75NTR-associated loss of survival than breast (MCF7) and fibroblast (3T3) cells. Transfection of the PC-3 prostate cell line with a dominant-negative form of p75NTR before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75NTR levels and inhibition of survival. Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75NTR by DIM in the PC-3 prostate cell line. DIM treatment induced phosphorylation of p38 MAPK as early as within 1 minute. Collectively, we identify DIM as an indole capable of inducing p75NTR-dependent apoptosis via the p38 MAPK pathway in prostate cancer cells.

Key Words: DIM • p75NTR • p38 MAPK • indoles







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.